Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research ...

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report ...

RBC Capital analyst Gregory Renza maintained a Buy rating on ADC Therapeutics (ADCT – Research Report) on January 7 and set a price target of ...